image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Week of July 19, 2021

Date Requested Closing Price Volume Split Adjustment Factor Open Price Day High Day Low
July 19, 2021 $26.24 638,263 1:1 $25.58 $26.96 $25.40
July 20, 2021 $28.78 885,645 1:1 $26.30 $29.00 $26.30
July 21, 2021 $30.11 1,329,303 1:1 $28.50 $30.18 $28.23
July 22, 2021 $30.68 921,833 1:1 $30.10 $30.87 $29.63
July 23, 2021 $30.72 1,235,273 1:1 $30.75 $31.12 $29.37

NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown above. The closing price above is not necessarily indicative of future price performance.

Data Provided by Refinitiv. Minimum 15 minutes delayed.